Literature DB >> 25344841

Proteochemometric model for predicting the inhibition of penicillin-binding proteins.

Sunanta Nabu1, Chanin Nantasenamat, Wiwat Owasirikul, Ratana Lawung, Chartchalerm Isarankura-Na-Ayudhya, Maris Lapins, Jarl E S Wikberg, Virapong Prachayasittikul.   

Abstract

Neisseria gonorrhoeae infection threatens to become an untreatable sexually transmitted disease in the near future owing to the increasing emergence of N. gonorrhoeae strains with reduced susceptibility and resistance to the extended-spectrum cephalosporins (ESCs), i.e. ceftriaxone and cefixime, which are the last remaining option for first-line treatment of gonorrhea. Alteration of the penA gene, encoding penicillin-binding protein 2 (PBP2), is the main mechanism conferring penicillin resistance including reduced susceptibility and resistance to ESCs. To predict and investigate putative amino acid mutations causing β-lactam resistance particularly for ESCs, we applied proteochemometric modeling to generalize N. gonorrhoeae susceptibility data for predicting the interaction of PBP2 with therapeutic β-lactam antibiotics. This was afforded by correlating publicly available data on antimicrobial susceptibility of wild-type and mutant N. gonorrhoeae strains for penicillin-G, cefixime and ceftriaxone with 50 PBP2 protein sequence data using partial least-squares projections to latent structures. The generated model revealed excellent predictability (R2=0.91, Q2=0.77, QExt2=0.78). Moreover, our model identified amino acid mutations in PBP2 with the highest impact on antimicrobial susceptibility and provided information on physicochemical properties of amino acid mutations affecting antimicrobial susceptibility. Our model thus provided insight into the physicochemical basis for resistance development in PBP2 suggesting its use for predicting and monitoring novel PBP2 mutations that may emerge in the future.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25344841     DOI: 10.1007/s10822-014-9809-0

Source DB:  PubMed          Journal:  J Comput Aided Mol Des        ISSN: 0920-654X            Impact factor:   3.686


  59 in total

1.  Amino acid substitutions in mosaic penicillin-binding protein 2 associated with reduced susceptibility to cefixime in clinical isolates of Neisseria gonorrhoeae.

Authors:  Sho Takahata; Nami Senju; Yumi Osaki; Takuji Yoshida; Takashi Ida
Journal:  Antimicrob Agents Chemother       Date:  2006-08-28       Impact factor: 5.191

2.  Analysis of pharmacology data and the prediction of adverse drug reactions and off-target effects from chemical structure.

Authors:  Andreas Bender; Josef Scheiber; Meir Glick; John W Davies; Kamal Azzaoui; Jacques Hamon; Laszlo Urban; Steven Whitebread; Jeremy L Jenkins
Journal:  ChemMedChem       Date:  2007-06       Impact factor: 3.466

3.  High-level cefixime- and ceftriaxone-resistant Neisseria gonorrhoeae in France: novel penA mosaic allele in a successful international clone causes treatment failure.

Authors:  Magnus Unemo; Daniel Golparian; Robert Nicholas; Makoto Ohnishi; Anne Gallay; Patrice Sednaoui
Journal:  Antimicrob Agents Chemother       Date:  2011-12-12       Impact factor: 5.191

4.  Molecular and structural analysis of mosaic variants of penicillin-binding protein 2 conferring decreased susceptibility to expanded-spectrum cephalosporins in Neisseria gonorrhoeae: role of epistatic mutations.

Authors:  Joshua Tomberg; Magnus Unemo; Christopher Davies; Robert A Nicholas
Journal:  Biochemistry       Date:  2010-09-21       Impact factor: 3.162

5.  Identification of amino acids conferring high-level resistance to expanded-spectrum cephalosporins in the penA gene from Neisseria gonorrhoeae strain H041.

Authors:  Joshua Tomberg; Magnus Unemo; Makoto Ohnishi; Christopher Davies; Robert A Nicholas
Journal:  Antimicrob Agents Chemother       Date:  2013-04-15       Impact factor: 5.191

6.  Various penA mutations together with mtrR, porB and ponA mutations in Neisseria gonorrhoeae isolates with reduced susceptibility to cefixime or ceftriaxone.

Authors:  Sang-Guk Lee; Hyukmin Lee; Seok Hoon Jeong; Dongeun Yong; Gyung Tae Chung; Yeong Seon Lee; Yunsop Chong; Kyungwon Lee
Journal:  J Antimicrob Chemother       Date:  2010-01-21       Impact factor: 5.790

7.  Antimicrobial susceptibility and penicillin-binding protein 1 and 2 mutations in Neisseria gonorrhoeae isolated from male urethritis in Sapporo, Japan.

Authors:  Satoshi Takahashi; Yuichiro Kurimura; Jiro Hashimoto; Teruhisa Uehara; Yoshiki Hiyama; Akihiko Iwasawa; Masahiro Nishimura; Kenichi Sunaoshi; Koichi Takeda; Nobukazu Suzuki; Taiji Tsukamoto
Journal:  J Infect Chemother       Date:  2012-07-14       Impact factor: 2.211

8.  Proteochemometric modeling of the bioactivity spectra of HIV-1 protease inhibitors by introducing protein-ligand interaction fingerprint.

Authors:  Qi Huang; Haixiao Jin; Qi Liu; Qiong Wu; Hong Kang; Zhiwei Cao; Ruixin Zhu
Journal:  PLoS One       Date:  2012-07-27       Impact factor: 3.240

9.  Screening of selective histone deacetylase inhibitors by proteochemometric modeling.

Authors:  Dingfeng Wu; Qi Huang; Yida Zhang; Qingchen Zhang; Qi Liu; Jun Gao; Zhiwei Cao; Ruixin Zhu
Journal:  BMC Bioinformatics       Date:  2012-08-22       Impact factor: 3.169

10.  Proteochemometric modeling of HIV protease susceptibility.

Authors:  Maris Lapins; Martin Eklund; Ola Spjuth; Peteris Prusis; Jarl E S Wikberg
Journal:  BMC Bioinformatics       Date:  2008-04-10       Impact factor: 3.169

View more
  3 in total

1.  Unsupervised Representation Learning for Proteochemometric Modeling.

Authors:  Paul T Kim; Robin Winter; Djork-Arné Clevert
Journal:  Int J Mol Sci       Date:  2021-11-28       Impact factor: 5.923

2.  Proteochemometric Method for pIC50 Prediction of Flaviviridae.

Authors:  Divye Singh; Avani Mahadik; Shraddha Surana; Pooja Arora
Journal:  Biomed Res Int       Date:  2022-09-15       Impact factor: 3.246

Review 3.  Resistance to β-Lactams in Neisseria ssp Due to Chromosomally Encoded Penicillin-Binding Proteins.

Authors:  André Zapun; Cécile Morlot; Muhamed-Kheir Taha
Journal:  Antibiotics (Basel)       Date:  2016-09-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.